Generex Biotechnology Signs Clinical Trial Agreement With the NSABP Foundation, Inc. for Phase II Clinical Trial of AE37 in Combination With Pembrolizumab (Keytruda®) for Treatment of Triple-Negative Breast Cancer
NSABP to Provide Clinical Trial and Site Management Services for Antigen Express and Research Partner Merck on AE37/Keytruda® Combination Trial
Read More